1	4	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Discussion	_	_	NN	_	_	_	_	_


1	There	_	_	EX	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	little	_	_	JJ	_	_	_	_	_
4	published	_	_	VBN	_	_	_	_	_
5	literature	_	_	NN	_	_	_	_	_
6	considering	_	_	VBG	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	role	_	_	NN	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	palliative	_	_	JJ	_	_	_	_	_
11	radiotherapy	_	_	NN	_	_	_	_	_
12	in	_	_	IN	_	_	_	_	_
13	metastatic	_	_	JJ	_	_	_	_	_
14	sarcoma	_	_	NN	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	although	_	_	IN	_	_	_	_	_
17	it	_	_	PRP	_	_	_	_	_
18	is	_	_	VBZ	_	_	_	_	_
19	recommended	_	_	VBN	_	_	_	_	_
20	as	_	_	IN	_	_	_	_	_
21	a	_	_	DT	_	_	_	_	_
22	treatment	_	_	NN	_	_	_	_	_
23	option	_	_	NN	_	_	_	_	_
24	for	_	_	IN	_	_	_	_	_
25	palliation	_	_	NN	_	_	_	_	_
26	by	_	_	IN	_	_	_	_	_
27	both	_	_	CC	_	_	_	_	_
28	the	_	_	DT	_	_	_	_	_
29	UK	_	_	NNP	_	_	_	_	_
30	bone	_	_	NN	_	_	_	_	_
31	and	_	_	CC	_	_	_	_	_
32	soft	_	_	JJ	_	_	_	_	_
33	tissue	_	_	NN	_	_	_	_	_
34	sarcoma	_	_	NN	_	_	_	_	_
35	guidelines	_	_	NNS	_	_	_	_	_
36	and	_	_	CC	_	_	_	_	_
37	the	_	_	DT	_	_	_	_	_
38	European	_	_	NNP	_	_	_	_	_
39	Society	_	_	NNP	_	_	_	_	_
40	of	_	_	IN	_	_	_	_	_
41	Medical	_	_	NNP	_	_	_	_	_
42	Oncology	_	_	NNP	_	_	_	_	_
43	(	_	_	-LRB-	_	_	_	_	_
44	ESMO	_	_	NNP	_	_	_	_	_
45	)	_	_	-RRB-	_	_	_	_	_
46	guidelines	_	_	NNS	_	_	_	_	_
47	.	_	_	.	_	_	_	_	_


1	To	_	_	TO	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	authors	_	_	NNS	_	_	_	_	_
4	’	_	_	POS	_	_	_	_	_
5	knowledge	_	_	NN	_	_	_	_	_
6	this	_	_	DT	_	_	_	_	_
7	is	_	_	VBZ	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	largest	_	_	JJS	_	_	_	_	_
10	retrospective	_	_	JJ	_	_	_	_	_
11	study	_	_	NN	_	_	_	_	_
12	published	_	_	VBN	_	_	_	_	_
13	to	_	_	TO	_	_	_	_	_
14	date	_	_	NN	_	_	_	_	_
15	reviewing	_	_	VBG	_	_	_	_	_
16	the	_	_	DT	_	_	_	_	_
17	use	_	_	NN	_	_	_	_	_
18	of	_	_	IN	_	_	_	_	_
19	palliative	_	_	JJ	_	_	_	_	_
20	radiotherapy	_	_	NN	_	_	_	_	_
21	for	_	_	IN	_	_	_	_	_
22	sarcoma	_	_	NN	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	results	_	_	NNS	_	_	_	_	_
3	confirm	_	_	VBP	_	_	_	_	_
4	that	_	_	IN	_	_	_	_	_
5	palliative	_	_	JJ	_	_	_	_	_
6	radiotherapy	_	_	NN	_	_	_	_	_
7	can	_	_	MD	_	_	_	_	_
8	successfully	_	_	RB	_	_	_	_	_
9	provide	_	_	VB	_	_	_	_	_
10	symptomatic	_	_	JJ	_	_	_	_	_
11	benefit	_	_	NN	_	_	_	_	_
12	to	_	_	TO	_	_	_	_	_
13	patients	_	_	NNS	_	_	_	_	_
14	with	_	_	IN	_	_	_	_	_
15	metastatic	_	_	JJ	_	_	_	_	_
16	sarcoma	_	_	NN	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	study	_	_	NN	_	_	_	_	_
3	is	_	_	VBZ	_	_	_	_	_
4	limited	_	_	VBN	_	_	_	_	_
5	by	_	_	IN	_	_	_	_	_
6	being	_	_	VBG	_	_	_	_	_
7	retrospective	_	_	JJ	_	_	_	_	_
8	such	_	_	JJ	_	_	_	_	_
9	that	_	_	IN	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	assessment	_	_	NN	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	symptomatic	_	_	JJ	_	_	_	_	_
14	improvement	_	_	NN	_	_	_	_	_
15	could	_	_	MD	_	_	_	_	_
16	only	_	_	RB	_	_	_	_	_
17	be	_	_	VB	_	_	_	_	_
18	assessed	_	_	VBN	_	_	_	_	_
19	from	_	_	IN	_	_	_	_	_
20	documentation	_	_	NN	_	_	_	_	_
21	in	_	_	IN	_	_	_	_	_
22	medical	_	_	JJ	_	_	_	_	_
23	records	_	_	NNS	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	It	_	_	PRP	_	_	_	_	_
2	was	_	_	VBD	_	_	_	_	_
3	therefore	_	_	RB	_	_	_	_	_
4	not	_	_	RB	_	_	_	_	_
5	possible	_	_	JJ	_	_	_	_	_
6	to	_	_	TO	_	_	_	_	_
7	quantify	_	_	VB	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	amount	_	_	NN	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	symptomatic	_	_	JJ	_	_	_	_	_
12	improvement	_	_	NN	_	_	_	_	_
13	seen	_	_	VBN	_	_	_	_	_
14	or	_	_	CC	_	_	_	_	_
15	indeed	_	_	RB	_	_	_	_	_
16	to	_	_	TO	_	_	_	_	_
17	be	_	_	VB	_	_	_	_	_
18	certain	_	_	JJ	_	_	_	_	_
19	of	_	_	IN	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	accuracy	_	_	NN	_	_	_	_	_
22	of	_	_	IN	_	_	_	_	_
23	the	_	_	DT	_	_	_	_	_
24	results	_	_	NNS	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	aim	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	this	_	_	DT	_	_	_	_	_
5	review	_	_	NN	_	_	_	_	_
6	,	_	_	,	_	_	_	_	_
7	however	_	_	RB	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	was	_	_	VBD	_	_	_	_	_
10	to	_	_	TO	_	_	_	_	_
11	confirm	_	_	VB	_	_	_	_	_
12	that	_	_	IN	_	_	_	_	_
13	radiotherapy	_	_	NN	_	_	_	_	_
14	does	_	_	VBZ	_	_	_	_	_
15	have	_	_	VB	_	_	_	_	_
16	a	_	_	DT	_	_	_	_	_
17	role	_	_	NN	_	_	_	_	_
18	in	_	_	IN	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	palliation	_	_	NN	_	_	_	_	_
21	of	_	_	IN	_	_	_	_	_
22	advanced	_	_	JJ	_	_	_	_	_
23	sarcomas	_	_	NNS	_	_	_	_	_
24	and	_	_	CC	_	_	_	_	_
25	to	_	_	TO	_	_	_	_	_
26	guide	_	_	VB	_	_	_	_	_
27	future	_	_	JJ	_	_	_	_	_
28	prospective	_	_	JJ	_	_	_	_	_
29	studies	_	_	NNS	_	_	_	_	_
30	to	_	_	TO	_	_	_	_	_
31	gain	_	_	VB	_	_	_	_	_
32	more	_	_	RBR	_	_	_	_	_
33	accurate	_	_	JJ	_	_	_	_	_
34	evidence	_	_	NN	_	_	_	_	_
35	of	_	_	IN	_	_	_	_	_
36	the	_	_	DT	_	_	_	_	_
37	use	_	_	NN	_	_	_	_	_
38	of	_	_	IN	_	_	_	_	_
39	palliative	_	_	JJ	_	_	_	_	_
40	radiotherapy	_	_	NN	_	_	_	_	_
41	in	_	_	IN	_	_	_	_	_
42	this	_	_	DT	_	_	_	_	_
43	setting	_	_	NN	_	_	_	_	_
44	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	addition	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	this	_	_	DT	_	_	_	_	_
5	study	_	_	NN	_	_	_	_	_
6	was	_	_	VBD	_	_	_	_	_
7	limited	_	_	VBN	_	_	_	_	_
8	by	_	_	IN	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	heterogeneous	_	_	JJ	_	_	_	_	_
11	population	_	_	NN	_	_	_	_	_
12	studied	_	_	VBN	_	_	_	_	_
13	.	_	_	.	_	_	_	_	_


1	Both	_	_	DT	_	_	_	_	_
2	soft	_	_	JJ	_	_	_	_	_
3	tissue	_	_	NN	_	_	_	_	_
4	and	_	_	CC	_	_	_	_	_
5	bone	_	_	NN	_	_	_	_	_
6	sarcomas	_	_	NNS	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	multiple	_	_	JJ	_	_	_	_	_
9	types	_	_	NNS	_	_	_	_	_
10	were	_	_	VBD	_	_	_	_	_
11	included	_	_	VBN	_	_	_	_	_
12	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	radiobiology	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	different	_	_	JJ	_	_	_	_	_
6	subtypes	_	_	NNS	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	sarcoma	_	_	NN	_	_	_	_	_
9	has	_	_	VBZ	_	_	_	_	_
10	not	_	_	RB	_	_	_	_	_
11	been	_	_	VBN	_	_	_	_	_
12	well	_	_	RB	_	_	_	_	_
13	studied	_	_	VBN	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	but	_	_	CC	_	_	_	_	_
16	it	_	_	PRP	_	_	_	_	_
17	is	_	_	VBZ	_	_	_	_	_
18	accepted	_	_	VBN	_	_	_	_	_
19	that	_	_	IN	_	_	_	_	_
20	these	_	_	DT	_	_	_	_	_
21	tumours	_	_	NNS	_	_	_	_	_
22	tend	_	_	VBP	_	_	_	_	_
23	to	_	_	TO	_	_	_	_	_
24	be	_	_	VB	_	_	_	_	_
25	relatively	_	_	RB	_	_	_	_	_
26	radio-resistant	_	_	JJ	_	_	_	_	_
27	,	_	_	,	_	_	_	_	_
28	with	_	_	IN	_	_	_	_	_
29	a	_	_	DT	_	_	_	_	_
30	high	_	_	JJ	_	_	_	_	_
31	alpha	_	_	NN	_	_	_	_	_
32	beta	_	_	NN	_	_	_	_	_
33	ratio	_	_	NN	_	_	_	_	_
34	.	_	_	.	_	_	_	_	_


1	There	_	_	EX	_	_	_	_	_
2	have	_	_	VBP	_	_	_	_	_
3	been	_	_	VBN	_	_	_	_	_
4	several	_	_	JJ	_	_	_	_	_
5	publications	_	_	NNS	_	_	_	_	_
6	considering	_	_	VBG	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	role	_	_	NN	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	palliative	_	_	JJ	_	_	_	_	_
11	radiotherapy	_	_	NN	_	_	_	_	_
12	for	_	_	IN	_	_	_	_	_
13	other	_	_	JJ	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	more	_	_	RBR	_	_	_	_	_
16	common	_	_	JJ	_	_	_	_	_
17	solid	_	_	JJ	_	_	_	_	_
18	tumour	_	_	NN	_	_	_	_	_
19	types	_	_	NNS	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	A	_	_	DT	_	_	_	_	_
2	meta-analysis	_	_	NN	_	_	_	_	_
3	has	_	_	VBZ	_	_	_	_	_
4	shown	_	_	VBN	_	_	_	_	_
5	that	_	_	IN	_	_	_	_	_
6	when	_	_	WRB	_	_	_	_	_
7	treating	_	_	VBG	_	_	_	_	_
8	bone	_	_	NN	_	_	_	_	_
9	metastases	_	_	NNS	_	_	_	_	_
10	from	_	_	IN	_	_	_	_	_
11	a	_	_	DT	_	_	_	_	_
12	number	_	_	NN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	different	_	_	JJ	_	_	_	_	_
15	primary	_	_	JJ	_	_	_	_	_
16	tumour	_	_	NN	_	_	_	_	_
17	sites	_	_	NNS	_	_	_	_	_
18	and	_	_	CC	_	_	_	_	_
19	histology	_	_	NN	_	_	_	_	_
20	’s	_	_	POS	_	_	_	_	_
21	,	_	_	,	_	_	_	_	_
22	there	_	_	EX	_	_	_	_	_
23	appears	_	_	VBZ	_	_	_	_	_
24	to	_	_	TO	_	_	_	_	_
25	be	_	_	VB	_	_	_	_	_
26	little	_	_	JJ	_	_	_	_	_
27	short-term	_	_	JJ	_	_	_	_	_
28	symptomatic	_	_	JJ	_	_	_	_	_
29	benefit	_	_	NN	_	_	_	_	_
30	in	_	_	IN	_	_	_	_	_
31	a	_	_	DT	_	_	_	_	_
32	fractionated	_	_	VBN	_	_	_	_	_
33	course	_	_	NN	_	_	_	_	_
34	of	_	_	IN	_	_	_	_	_
35	radiotherapy	_	_	NN	_	_	_	_	_
36	,	_	_	,	_	_	_	_	_
37	compared	_	_	VBN	_	_	_	_	_
38	to	_	_	TO	_	_	_	_	_
39	a	_	_	DT	_	_	_	_	_
40	single	_	_	JJ	_	_	_	_	_
41	fraction	_	_	NN	_	_	_	_	_
42	.	_	_	.	_	_	_	_	_


1	Most	_	_	JJS	_	_	_	_	_
2	oncologists	_	_	NNS	_	_	_	_	_
3	therefore	_	_	RB	_	_	_	_	_
4	advocate	_	_	VBP	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	use	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	a	_	_	DT	_	_	_	_	_
9	single	_	_	JJ	_	_	_	_	_
10	fraction	_	_	NN	_	_	_	_	_
11	to	_	_	TO	_	_	_	_	_
12	control	_	_	VB	_	_	_	_	_
13	pain	_	_	NN	_	_	_	_	_
14	secondary	_	_	JJ	_	_	_	_	_
15	to	_	_	TO	_	_	_	_	_
16	bone	_	_	NN	_	_	_	_	_
17	metastases	_	_	NNS	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	With	_	_	IN	_	_	_	_	_
2	longer	_	_	JJR	_	_	_	_	_
3	follow-up	_	_	NN	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	however	_	_	RB	_	_	_	_	_
6	,	_	_	,	_	_	_	_	_
7	it	_	_	PRP	_	_	_	_	_
8	seems	_	_	VBZ	_	_	_	_	_
9	that	_	_	IN	_	_	_	_	_
10	patients	_	_	NNS	_	_	_	_	_
11	treated	_	_	VBN	_	_	_	_	_
12	with	_	_	IN	_	_	_	_	_
13	a	_	_	DT	_	_	_	_	_
14	fractionated	_	_	VBN	_	_	_	_	_
15	course	_	_	NN	_	_	_	_	_
16	of	_	_	IN	_	_	_	_	_
17	palliative	_	_	JJ	_	_	_	_	_
18	radiotherapy	_	_	NN	_	_	_	_	_
19	are	_	_	VBP	_	_	_	_	_
20	less	_	_	RBR	_	_	_	_	_
21	likely	_	_	JJ	_	_	_	_	_
22	to	_	_	TO	_	_	_	_	_
23	need	_	_	VB	_	_	_	_	_
24	retreatment	_	_	NN	_	_	_	_	_
25	than	_	_	IN	_	_	_	_	_
26	those	_	_	DT	_	_	_	_	_
27	given	_	_	VBN	_	_	_	_	_
28	a	_	_	DT	_	_	_	_	_
29	single	_	_	JJ	_	_	_	_	_
30	fraction	_	_	NN	_	_	_	_	_
31	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	study	_	_	NN	_	_	_	_	_
3	demonstrates	_	_	VBZ	_	_	_	_	_
4	that	_	_	IN	_	_	_	_	_
5	selected	_	_	VBN	_	_	_	_	_
6	patients	_	_	NNS	_	_	_	_	_
7	with	_	_	IN	_	_	_	_	_
8	advanced	_	_	JJ	_	_	_	_	_
9	sarcoma	_	_	NN	_	_	_	_	_
10	can	_	_	MD	_	_	_	_	_
11	benefit	_	_	VB	_	_	_	_	_
12	from	_	_	IN	_	_	_	_	_
13	palliative	_	_	JJ	_	_	_	_	_
14	radiotherapy	_	_	NN	_	_	_	_	_
15	provided	_	_	VBN	_	_	_	_	_
16	their	_	_	PRP$	_	_	_	_	_
17	prognosis	_	_	NN	_	_	_	_	_
18	is	_	_	VBZ	_	_	_	_	_
19	long	_	_	JJ	_	_	_	_	_
20	enough	_	_	RB	_	_	_	_	_
21	for	_	_	IN	_	_	_	_	_
22	the	_	_	DT	_	_	_	_	_
23	benefits	_	_	NNS	_	_	_	_	_
24	from	_	_	IN	_	_	_	_	_
25	radiotherapy	_	_	NN	_	_	_	_	_
26	,	_	_	,	_	_	_	_	_
27	in	_	_	IN	_	_	_	_	_
28	terms	_	_	NNS	_	_	_	_	_
29	of	_	_	IN	_	_	_	_	_
30	symptomatic	_	_	JJ	_	_	_	_	_
31	improvement	_	_	NN	_	_	_	_	_
32	,	_	_	,	_	_	_	_	_
33	to	_	_	TO	_	_	_	_	_
34	outweigh	_	_	VB	_	_	_	_	_
35	the	_	_	DT	_	_	_	_	_
36	inconvenience	_	_	NN	_	_	_	_	_
37	of	_	_	IN	_	_	_	_	_
38	undergoing	_	_	VBG	_	_	_	_	_
39	radiotherapy	_	_	NN	_	_	_	_	_
40	and	_	_	CC	_	_	_	_	_
41	the	_	_	DT	_	_	_	_	_
42	associated	_	_	VBN	_	_	_	_	_
43	side	_	_	NN	_	_	_	_	_
44	effects	_	_	NNS	_	_	_	_	_
45	that	_	_	WDT	_	_	_	_	_
46	they	_	_	PRP	_	_	_	_	_
47	may	_	_	MD	_	_	_	_	_
48	suffer	_	_	VB	_	_	_	_	_
49	.	_	_	.	_	_	_	_	_


1	As	_	_	IN	_	_	_	_	_
2	sarcomas	_	_	NNS	_	_	_	_	_
3	are	_	_	VBP	_	_	_	_	_
4	felt	_	_	VBN	_	_	_	_	_
5	to	_	_	TO	_	_	_	_	_
6	be	_	_	VB	_	_	_	_	_
7	intrinsically	_	_	RB	_	_	_	_	_
8	radio-resistant	_	_	JJ	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	it	_	_	PRP	_	_	_	_	_
11	can	_	_	MD	_	_	_	_	_
12	be	_	_	VB	_	_	_	_	_
13	hypothesized	_	_	VBN	_	_	_	_	_
14	that	_	_	IN	_	_	_	_	_
15	a	_	_	DT	_	_	_	_	_
16	single	_	_	JJ	_	_	_	_	_
17	fraction	_	_	NN	_	_	_	_	_
18	of	_	_	IN	_	_	_	_	_
19	palliative	_	_	JJ	_	_	_	_	_
20	radiotherapy	_	_	NN	_	_	_	_	_
21	may	_	_	MD	_	_	_	_	_
22	not	_	_	RB	_	_	_	_	_
23	be	_	_	VB	_	_	_	_	_
24	sufficient	_	_	JJ	_	_	_	_	_
25	to	_	_	TO	_	_	_	_	_
26	offer	_	_	VB	_	_	_	_	_
27	adequate	_	_	JJ	_	_	_	_	_
28	symptomatic	_	_	JJ	_	_	_	_	_
29	benefit	_	_	NN	_	_	_	_	_
30	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	results	_	_	NNS	_	_	_	_	_
3	presented	_	_	VBD	_	_	_	_	_
4	here	_	_	RB	_	_	_	_	_
5	suggest	_	_	VB	_	_	_	_	_
6	a	_	_	DT	_	_	_	_	_
7	higher	_	_	JJR	_	_	_	_	_
8	symptomatic	_	_	JJ	_	_	_	_	_
9	response	_	_	NN	_	_	_	_	_
10	rate	_	_	NN	_	_	_	_	_
11	with	_	_	IN	_	_	_	_	_
12	a	_	_	DT	_	_	_	_	_
13	biological	_	_	JJ	_	_	_	_	_
14	effective	_	_	JJ	_	_	_	_	_
15	dose	_	_	NN	_	_	_	_	_
16	(	_	_	-LRB-	_	_	_	_	_
17	BED	_	_	NN	_	_	_	_	_
18	)	_	_	-RRB-	_	_	_	_	_
19	of	_	_	IN	_	_	_	_	_
20	50	_	_	CD	_	_	_	_	_
21	or	_	_	CC	_	_	_	_	_
22	greater	_	_	JJR	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	Figure	_	_	NN	_	_	_	_	_
2	3	_	_	CD	_	_	_	_	_


1	b	_	_	NNP	_	_	_	_	_
2	demonstrates	_	_	VBZ	_	_	_	_	_
3	an	_	_	DT	_	_	_	_	_
4	increase	_	_	NN	_	_	_	_	_
5	in	_	_	IN	_	_	_	_	_
6	response	_	_	NN	_	_	_	_	_
7	rate	_	_	NN	_	_	_	_	_
8	with	_	_	IN	_	_	_	_	_
9	increasing	_	_	VBG	_	_	_	_	_
10	BED	_	_	NN	_	_	_	_	_
11	up	_	_	IN	_	_	_	_	_
12	to	_	_	TO	_	_	_	_	_
13	50	_	_	CD	_	_	_	_	_
14	Gy4	_	_	NNP	_	_	_	_	_
15	.	_	_	.	_	_	_	_	_


1	Beyond	_	_	IN	_	_	_	_	_
2	this	_	_	DT	_	_	_	_	_
3	point	_	_	NN	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	response	_	_	NN	_	_	_	_	_
6	is	_	_	VBZ	_	_	_	_	_
7	maintained	_	_	VBN	_	_	_	_	_
8	but	_	_	CC	_	_	_	_	_
9	does	_	_	VBZ	_	_	_	_	_
10	not	_	_	RB	_	_	_	_	_
11	appear	_	_	VB	_	_	_	_	_
12	to	_	_	TO	_	_	_	_	_
13	increase	_	_	VB	_	_	_	_	_
14	further	_	_	RBR	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	suggesting	_	_	VBG	_	_	_	_	_
17	very	_	_	RB	_	_	_	_	_
18	high	_	_	JJ	_	_	_	_	_
19	doses	_	_	NNS	_	_	_	_	_
20	of	_	_	IN	_	_	_	_	_
21	palliative	_	_	JJ	_	_	_	_	_
22	radiotherapy	_	_	NN	_	_	_	_	_
23	may	_	_	MD	_	_	_	_	_
24	not	_	_	RB	_	_	_	_	_
25	be	_	_	VB	_	_	_	_	_
26	necessary	_	_	JJ	_	_	_	_	_
27	to	_	_	TO	_	_	_	_	_
28	achieve	_	_	VB	_	_	_	_	_
29	a	_	_	DT	_	_	_	_	_
30	good	_	_	JJ	_	_	_	_	_
31	symptomatic	_	_	JJ	_	_	_	_	_
32	response	_	_	NN	_	_	_	_	_
33	in	_	_	IN	_	_	_	_	_
34	this	_	_	DT	_	_	_	_	_
35	patient	_	_	NN	_	_	_	_	_
36	group	_	_	NN	_	_	_	_	_
37	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	one	_	_	CD	_	_	_	_	_
3	apparent	_	_	JJ	_	_	_	_	_
4	outlier	_	_	NN	_	_	_	_	_
5	in	_	_	IN	_	_	_	_	_


1	Figure	_	_	NN	_	_	_	_	_
2	3	_	_	CD	_	_	_	_	_


1	b	_	_	NNP	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	100	_	_	CD	_	_	_	_	_
5	%	_	_	NN	_	_	_	_	_
6	symptomatic	_	_	JJ	_	_	_	_	_
7	response	_	_	NN	_	_	_	_	_
8	in	_	_	IN	_	_	_	_	_
9	patients	_	_	NNS	_	_	_	_	_
10	receiving	_	_	VBG	_	_	_	_	_
11	a	_	_	DT	_	_	_	_	_
12	BED	_	_	NN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	30	_	_	CD	_	_	_	_	_
15	–	_	_	TO	_	_	_	_	_
16	39.9	_	_	CD	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	this	_	_	DT	_	_	_	_	_
19	is	_	_	VBZ	_	_	_	_	_
20	likely	_	_	JJ	_	_	_	_	_
21	to	_	_	TO	_	_	_	_	_
22	be	_	_	VB	_	_	_	_	_
23	an	_	_	DT	_	_	_	_	_
24	outlier	_	_	NN	_	_	_	_	_
25	as	_	_	IN	_	_	_	_	_
26	there	_	_	EX	_	_	_	_	_
27	was	_	_	VBD	_	_	_	_	_
28	only	_	_	RB	_	_	_	_	_
29	one	_	_	CD	_	_	_	_	_
30	patient	_	_	NN	_	_	_	_	_
31	in	_	_	IN	_	_	_	_	_
32	this	_	_	DT	_	_	_	_	_
33	group	_	_	NN	_	_	_	_	_
34	.	_	_	.	_	_	_	_	_


1	Because	_	_	IN	_	_	_	_	_
2	of	_	_	IN	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	limited	_	_	JJ	_	_	_	_	_
5	evidence	_	_	NN	_	_	_	_	_
6	available	_	_	JJ	_	_	_	_	_
7	in	_	_	IN	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	use	_	_	NN	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	radiotherapy	_	_	NN	_	_	_	_	_
12	for	_	_	IN	_	_	_	_	_
13	palliation	_	_	NN	_	_	_	_	_
14	in	_	_	IN	_	_	_	_	_
15	sarcoma	_	_	NN	_	_	_	_	_
16	the	_	_	DT	_	_	_	_	_
17	Royal	_	_	NNP	_	_	_	_	_
18	College	_	_	NNP	_	_	_	_	_
19	of	_	_	IN	_	_	_	_	_
20	Radiologists	_	_	NNPS	_	_	_	_	_


1	Radiotherapy	_	_	NN	_	_	_	_	_
2	dose	_	_	NN	_	_	_	_	_
3	fractionation	_	_	NN	_	_	_	_	_
4	guidance	_	_	NN	_	_	_	_	_
5	(	_	_	-LRB-	_	_	_	_	_
6	3rd	_	_	JJ	_	_	_	_	_
7	edition	_	_	NN	_	_	_	_	_
8	)	_	_	-RRB-	_	_	_	_	_
9	recommends	_	_	VBZ	_	_	_	_	_
10	several	_	_	JJ	_	_	_	_	_
11	different	_	_	JJ	_	_	_	_	_
12	dose	_	_	NN	_	_	_	_	_
13	fractionation	_	_	NN	_	_	_	_	_
14	schedules	_	_	NNS	_	_	_	_	_
15	(	_	_	-LRB-	_	_	_	_	_
16	Table	_	_	NN	_	_	_	_	_
17	5	_	_	CD	_	_	_	_	_
18	)	_	_	-RRB-	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	Excluding	_	_	VBG	_	_	_	_	_
2	8	_	_	CD	_	_	_	_	_
3	Gy	_	_	NN	_	_	_	_	_
4	single	_	_	JJ	_	_	_	_	_
5	fraction	_	_	NN	_	_	_	_	_
6	and	_	_	CC	_	_	_	_	_
7	20	_	_	CD	_	_	_	_	_
8	Gy	_	_	NN	_	_	_	_	_
9	in	_	_	IN	_	_	_	_	_
10	5	_	_	CD	_	_	_	_	_
11	fractions	_	_	NNS	_	_	_	_	_
12	which	_	_	WDT	_	_	_	_	_
13	are	_	_	VBP	_	_	_	_	_
14	commonly	_	_	RB	_	_	_	_	_
15	used	_	_	VBN	_	_	_	_	_
16	schedules	_	_	NNS	_	_	_	_	_
17	for	_	_	IN	_	_	_	_	_
18	all	_	_	DT	_	_	_	_	_
19	solid	_	_	JJ	_	_	_	_	_
20	tumours	_	_	NNS	_	_	_	_	_
21	;	_	_	:	_	_	_	_	_
22	the	_	_	DT	_	_	_	_	_
23	remaining	_	_	VBG	_	_	_	_	_
24	recommended	_	_	VBN	_	_	_	_	_
25	dose	_	_	NN	_	_	_	_	_
26	fractionation	_	_	NN	_	_	_	_	_
27	schedules	_	_	NNS	_	_	_	_	_
28	all	_	_	DT	_	_	_	_	_
29	have	_	_	VBP	_	_	_	_	_
30	a	_	_	DT	_	_	_	_	_
31	BED	_	_	NN	_	_	_	_	_
32	of	_	_	IN	_	_	_	_	_
33	greater	_	_	JJR	_	_	_	_	_
34	than	_	_	IN	_	_	_	_	_
35	50	_	_	CD	_	_	_	_	_
36	Gy4	_	_	NN	_	_	_	_	_
37	.	_	_	.	_	_	_	_	_


1	Although	_	_	IN	_	_	_	_	_
2	this	_	_	DT	_	_	_	_	_
3	case	_	_	NN	_	_	_	_	_
4	series	_	_	NN	_	_	_	_	_
5	has	_	_	VBZ	_	_	_	_	_
6	demonstrated	_	_	VBN	_	_	_	_	_
7	that	_	_	IN	_	_	_	_	_
8	very	_	_	RB	_	_	_	_	_
9	high	_	_	JJ	_	_	_	_	_
10	doses	_	_	NNS	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	radiotherapy	_	_	NN	_	_	_	_	_
13	may	_	_	MD	_	_	_	_	_
14	not	_	_	RB	_	_	_	_	_
15	provide	_	_	VB	_	_	_	_	_
16	additional	_	_	JJ	_	_	_	_	_
17	short-term	_	_	JJ	_	_	_	_	_
18	symptomatic	_	_	JJ	_	_	_	_	_
19	benefit	_	_	NN	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	longer	_	_	JJR	_	_	_	_	_
22	courses	_	_	NNS	_	_	_	_	_
23	of	_	_	IN	_	_	_	_	_
24	radiotherapy	_	_	NN	_	_	_	_	_
25	may	_	_	MD	_	_	_	_	_
26	be	_	_	VB	_	_	_	_	_
27	considered	_	_	VBN	_	_	_	_	_
28	in	_	_	IN	_	_	_	_	_
29	patients	_	_	NNS	_	_	_	_	_
30	with	_	_	IN	_	_	_	_	_
31	a	_	_	DT	_	_	_	_	_
32	good	_	_	JJ	_	_	_	_	_
33	performance	_	_	NN	_	_	_	_	_
34	status	_	_	NN	_	_	_	_	_
35	and	_	_	CC	_	_	_	_	_
36	prognosis	_	_	NN	_	_	_	_	_
37	in	_	_	IN	_	_	_	_	_
38	an	_	_	DT	_	_	_	_	_
39	attempt	_	_	NN	_	_	_	_	_
40	to	_	_	TO	_	_	_	_	_
41	provide	_	_	VB	_	_	_	_	_
42	a	_	_	DT	_	_	_	_	_
43	longer	_	_	JJR	_	_	_	_	_
44	period	_	_	NN	_	_	_	_	_
45	of	_	_	IN	_	_	_	_	_
46	symptomatic	_	_	JJ	_	_	_	_	_
47	benefit	_	_	NN	_	_	_	_	_
48	without	_	_	IN	_	_	_	_	_
49	the	_	_	DT	_	_	_	_	_
50	need	_	_	NN	_	_	_	_	_
51	for	_	_	IN	_	_	_	_	_
52	retreatment	_	_	NN	_	_	_	_	_
53	.	_	_	.	_	_	_	_	_


1	A	_	_	DT	_	_	_	_	_
2	previously	_	_	RB	_	_	_	_	_
3	published	_	_	VBN	_	_	_	_	_
4	case	_	_	NN	_	_	_	_	_
5	series	_	_	NN	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	17	_	_	CD	_	_	_	_	_
8	patients	_	_	NNS	_	_	_	_	_
9	who	_	_	WP	_	_	_	_	_
10	received	_	_	VBD	_	_	_	_	_
11	palliative	_	_	JJ	_	_	_	_	_
12	radiotherapy	_	_	NN	_	_	_	_	_
13	for	_	_	IN	_	_	_	_	_
14	sarcoma	_	_	NN	_	_	_	_	_
15	using	_	_	VBG	_	_	_	_	_
16	39	_	_	CD	_	_	_	_	_
17	Gy	_	_	NN	_	_	_	_	_
18	in	_	_	IN	_	_	_	_	_
19	13	_	_	CD	_	_	_	_	_
20	fractions	_	_	NNS	_	_	_	_	_
21	over	_	_	IN	_	_	_	_	_
22	two	_	_	CD	_	_	_	_	_
23	and	_	_	CC	_	_	_	_	_
24	a	_	_	DT	_	_	_	_	_
25	half	_	_	CD	_	_	_	_	_
26	weeks	_	_	NNS	_	_	_	_	_
27	demonstrated	_	_	VBN	_	_	_	_	_
28	this	_	_	DT	_	_	_	_	_
29	was	_	_	VBD	_	_	_	_	_
30	well	_	_	RB	_	_	_	_	_
31	tolerated	_	_	VBN	_	_	_	_	_
32	and	_	_	CC	_	_	_	_	_
33	provided	_	_	VBN	_	_	_	_	_
34	high	_	_	JJ	_	_	_	_	_
35	rates	_	_	NNS	_	_	_	_	_
36	of	_	_	IN	_	_	_	_	_
37	durable	_	_	JJ	_	_	_	_	_
38	pain	_	_	NN	_	_	_	_	_
39	control	_	_	NN	_	_	_	_	_
40	.	_	_	.	_	_	_	_	_


1	Collection	_	_	NN	_	_	_	_	_
2	of	_	_	IN	_	_	_	_	_
3	survival	_	_	NN	_	_	_	_	_
4	data	_	_	NNS	_	_	_	_	_
5	may	_	_	MD	_	_	_	_	_
6	help	_	_	VB	_	_	_	_	_
7	to	_	_	TO	_	_	_	_	_
8	assess	_	_	VB	_	_	_	_	_
9	if	_	_	IN	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	correct	_	_	JJ	_	_	_	_	_
12	patients	_	_	NNS	_	_	_	_	_
13	are	_	_	VBP	_	_	_	_	_
14	being	_	_	VBG	_	_	_	_	_
15	offered	_	_	VBN	_	_	_	_	_
16	higher	_	_	JJR	_	_	_	_	_
17	dose	_	_	NN	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	longer	_	_	JJR	_	_	_	_	_
20	courses	_	_	NNS	_	_	_	_	_
21	of	_	_	IN	_	_	_	_	_
22	radiotherapy	_	_	NN	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	Figure	_	_	NN	_	_	_	_	_
2	4	_	_	CD	_	_	_	_	_


1	however	_	_	RB	_	_	_	_	_
2	does	_	_	VBZ	_	_	_	_	_
3	not	_	_	RB	_	_	_	_	_
4	appear	_	_	VB	_	_	_	_	_
5	to	_	_	TO	_	_	_	_	_
6	show	_	_	VB	_	_	_	_	_
7	any	_	_	DT	_	_	_	_	_
8	correlation	_	_	NN	_	_	_	_	_
9	between	_	_	IN	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	BED	_	_	NN	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	radiotherapy	_	_	NN	_	_	_	_	_
15	delivered	_	_	VBN	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	overall	_	_	JJ	_	_	_	_	_
18	survival	_	_	NN	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	Interpretation	_	_	NN	_	_	_	_	_
2	of	_	_	IN	_	_	_	_	_
3	this	_	_	DT	_	_	_	_	_
4	data	_	_	NN	_	_	_	_	_
5	is	_	_	VBZ	_	_	_	_	_
6	extremely	_	_	RB	_	_	_	_	_
7	limited	_	_	VBN	_	_	_	_	_
8	because	_	_	IN	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	heterogeneity	_	_	NN	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	patient	_	_	NN	_	_	_	_	_
15	population	_	_	NN	_	_	_	_	_
16	with	_	_	IN	_	_	_	_	_
17	multiple	_	_	JJ	_	_	_	_	_
18	different	_	_	JJ	_	_	_	_	_
19	histological	_	_	JJ	_	_	_	_	_
20	subtypes	_	_	NNS	_	_	_	_	_
21	and	_	_	CC	_	_	_	_	_
22	the	_	_	DT	_	_	_	_	_
23	small	_	_	JJ	_	_	_	_	_
24	numbers	_	_	NNS	_	_	_	_	_
25	of	_	_	IN	_	_	_	_	_
26	patients	_	_	NNS	_	_	_	_	_
27	treated	_	_	VBN	_	_	_	_	_
28	with	_	_	IN	_	_	_	_	_
29	each	_	_	DT	_	_	_	_	_
30	dose	_	_	NN	_	_	_	_	_
31	and	_	_	CC	_	_	_	_	_
32	fractionation	_	_	NN	_	_	_	_	_
33	schedule	_	_	NN	_	_	_	_	_
34	.	_	_	.	_	_	_	_	_


1	To	_	_	TO	_	_	_	_	_
2	gain	_	_	VB	_	_	_	_	_
3	a	_	_	DT	_	_	_	_	_
4	better	_	_	JJR	_	_	_	_	_
5	understanding	_	_	NN	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	most	_	_	RBS	_	_	_	_	_
9	appropriate	_	_	JJ	_	_	_	_	_
10	dose	_	_	NN	_	_	_	_	_
11	and	_	_	CC	_	_	_	_	_
12	fractionation	_	_	NN	_	_	_	_	_
13	schedules	_	_	NNS	_	_	_	_	_
14	for	_	_	IN	_	_	_	_	_
15	different	_	_	JJ	_	_	_	_	_
16	sarcoma	_	_	NN	_	_	_	_	_
17	subtypes	_	_	NNS	_	_	_	_	_
18	large	_	_	JJ	_	_	_	_	_
19	volume	_	_	NN	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	multicentre	_	_	NN	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	prospective	_	_	JJ	_	_	_	_	_
24	data	_	_	NN	_	_	_	_	_
25	collections	_	_	NNS	_	_	_	_	_
26	is	_	_	VBZ	_	_	_	_	_
27	required	_	_	VBN	_	_	_	_	_
28	using	_	_	VBG	_	_	_	_	_
29	a	_	_	DT	_	_	_	_	_
30	small	_	_	JJ	_	_	_	_	_
31	number	_	_	NN	_	_	_	_	_
32	of	_	_	IN	_	_	_	_	_
33	different	_	_	JJ	_	_	_	_	_
34	dose	_	_	NN	_	_	_	_	_
35	and	_	_	CC	_	_	_	_	_
36	fractionation	_	_	NN	_	_	_	_	_
37	schedules	_	_	NNS	_	_	_	_	_
38	,	_	_	,	_	_	_	_	_
39	ideally	_	_	RB	_	_	_	_	_
40	those	_	_	DT	_	_	_	_	_
41	outlined	_	_	VBN	_	_	_	_	_
42	by	_	_	IN	_	_	_	_	_
43	the	_	_	DT	_	_	_	_	_
44	Royal	_	_	NNP	_	_	_	_	_
45	College	_	_	NNP	_	_	_	_	_
46	of	_	_	IN	_	_	_	_	_
47	Radiologists	_	_	NNP	_	_	_	_	_
48	(	_	_	-LRB-	_	_	_	_	_
49	Table	_	_	NNP	_	_	_	_	_
50	5	_	_	CD	_	_	_	_	_
51	)	_	_	-RRB-	_	_	_	_	_
52	.	_	_	.	_	_	_	_	_

